Long-term treatment with atazanavir (ATV) in real life in Belgium: a retrospective observational cohort of 2264 HIV patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Long-term treatment with atazanavir (ATV) in real life in Belgium: a retrospective observational cohort of 2264 HIV patients

Published:2018-05-02 Issue:3 Volume:74 Page:143-150
ISSN:1784-3286
Container-title:Acta Clinica Belgica
language:en
Short-container-title:Acta Clinica Belgica

Author:

De Wit Stéphane¹^ORCID,Florence Eric²,Vandekerkhove Linos³,Goffard Jean-Christophe⁴^ORCID,Vandercam Bernard⁵,Van Wijngaerden Eric⁶,Moutschen Michel⁷,Demeester Rémy⁸,Lacor Patrick⁹,Delforge Marc¹,van Frankenhuijsen Maartje²^ORCID,Lacante Paul¹⁰

Affiliation:

1. Service des Maladies Infectieuses, CHU Saint-Pierre, Université Libre de Bruxelles, Brussels, Belgium

2. ITG Antwerpen, Antwerpen, Belgium

3. University Hospital Ghent, Ghent, Belgium

4. Hôpital Erasme Bruxelles, Bruxelles, Belgium

5. CU Saint-Luc, Bruxelles, Belgium

6. UZ Leuven, Leuven, Belgium

7. CHU Liège, Liège, Belgium

8. CHU Charleroi, Charleroi, Belgium

9. UZ Bruxelles, Jette, Belgium

10. Bristol-Myers Squibb, Bruxelles, Belgium

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17843286.2018.1462753

Reference21 articles.

1. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals

2. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

3. Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1–Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study

4. Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1

5. A Randomized, Double-blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3